|
|
|
|
|
|
by rocqua
1316 days ago
|
|
|
There are hints of tracking too many data points, and perhaps too much manual tracking. Also the story that, for very profitable drugs the approach is about speed of trials rather than cost. If that is pervasive then it might become standard. Heck, if that is where the money is, that is where carreers will gravitate to. |
|
|